Innovent Biologics Inc - Company Profile
Powered by 
All the data and insights you need on Innovent Biologics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Innovent Biologics Inc Strategy Report
- Understand Innovent Biologics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Innovent Biologics Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP3854806A4 | Search Report | NEUARTIGES INTERLEUKIN 2 UND SEINE VERWENDUNG | A61K38/00; A61K47/68; A61K47/6843; A61K47/6845; A61K47/6853; A61K47/6865; A61K47/6871; A61P31/12; A61P35/00; C07K14/55; C07K16/18; C07K16/248; C07K16/3007; C07K16/3053; C07K16/40; C07K2317/55; C07K2317/56; C07K2317/92; C07K2319/30; C12N15/81; C12P21/02 | September 21, 2022 |
| EP4056200A1 | Application | ARZNEIMITTELKOMBINATION AUS CHINOLINDERIVAT UND MONOKLONALEM PD-1-ANTIKÖRPER | A61K31/4709; A61K39/395; A61P35/00; C07K16/28 | September 14, 2022 |
| US20220281972A1 | Application | FORMULATION COMPRISING ANTI-PD-1/HER2 BISPECIFIC ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF | A61K2039/505; A61K47/26; A61K9/0019; A61P35/00; C07K16/2803 | September 08, 2022 |
| AU2021205144A1 | Application | Application of combination of anti-CD47 antibody and anti-CD20 antibody in preparation of drugs for preventing or treating tumors | A61K39/00; A61K39/395; A61P35/00; C07K16/28 | August 25, 2022 |
| WO2022174813A1 | Application | ANTI-GPRC5D×BCMA×CD3 TRISPECIFIC ANTIBODY AND USE THEREOF | August 25, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer